StreetInsider.com News Articles

Form DEF 14A PAVmed Inc. For: Feb 24

Tue, 24 Feb 2026 16:15:00 -0500

si-local-file:///var/storage/secattach/20260224/26051751.html

Form DEF 14A PAVmed Inc. For: Feb 24

Tue, 24 Feb 2026 16:15:00 -0500

si-local-file:///var/storage/secattach/20260224/26051751.html

Form D PAVmed Inc.

Tue, 17 Feb 2026 08:39:00 -0500

si-local-file:///var/storage/secattach/20260217/26007234.html

Form D PAVmed Inc.

Tue, 17 Feb 2026 08:39:00 -0500

si-local-file:///var/storage/secattach/20260217/26007234.html

Form PRE 14A PAVmed Inc. For: Feb 13

Fri, 13 Feb 2026 17:01:00 -0500

si-local-file:///var/storage/secattach/20260213/26001720.html

Form PRE 14A PAVmed Inc. For: Feb 13

Fri, 13 Feb 2026 17:01:00 -0500

si-local-file:///var/storage/secattach/20260213/26001720.html

Form 8-K PAVmed Inc. For: Feb 03

Wed, 04 Feb 2026 08:13:00 -0500

si-local-file:///var/storage/secattach/20260204/25943511.html

Form 8-K PAVmed Inc. For: Feb 03

Wed, 04 Feb 2026 08:13:00 -0500

si-local-file:///var/storage/secattach/20260204/25943511.html

PAVmed raises $45 million, eliminates convertible securities overhang

Wed, 04 Feb 2026 08:04:06 -0500

PAVmed Inc. (NASDAQ: PAVM) completed preferred stock and senior secured note financings totaling $45 million in gross proceeds, using the funds to eliminate all previously outstanding convertible securities.

The medical technology company issued $30 million of Series D Convertible Preferred Stock with associated warrants exercisable for up to an additional $30 million upon publication of a positive Medicare local coverage determination for its EsoGuard test. The company also issued a $15 million senior secured note with a February 2029 maturity.

PAVmed used $22.3 million in cash and the $15 million note to redeem all outstanding Series C Convertible Preferred Stock and retire

PAVmed raises $45 million, eliminates convertible securities overhang

Wed, 04 Feb 2026 08:04:06 -0500

PAVmed used $22.3 million in cash and the $15 million note to redeem all outstanding Series C Convertible Preferred Stock and retire

PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities

Wed, 04 Feb 2026 08:01:00 -0500

Series D Preferred Stock offering yielded $30 million of gross proceeds and includes warrants exercisable for up to an additional $30 million upon publication of a positive draft EsoGuard Medicare local coverage determination

Series D Preferred Stock convertible into common stock subject to stockholder approval at an upcoming special meeting

New senior secured note with three-year maturity yielded an additional $15 million of gross proceeds

Proceeds used to redeem and retire all previously outstanding convertible securities, eliminating a significant legacy capital structure overhang

Transactions yielded approximately $7.7 million in net cash proceeds, materially strengthening the Company's balance

PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities

Wed, 04 Feb 2026 08:01:00 -0500

Series D Preferred Stock offering yielded $30 million of gross proceeds and includes warrants exercisable for up to an additional $30 million upon publication of a positive draft EsoGuard Medicare local coverage determination
Series D Preferred Stock convertible into common stock subject to stockholder approval at an upcoming special meeting
New senior secured note with three-year maturity yielded an additional $15 million of gross proceeds
Proceeds used to redeem and retire all previously outstanding convertible securities, eliminating a significant legacy capital structure overhang
Transactions yielded approximately $7.7 million in net cash proceeds, materially strengthening the Company's balance

PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities

Wed, 04 Feb 2026 08:01:00 -0500

Series D Preferred Stock offering yielded $30 million of gross proceeds and includes warrants exercisable for up to an additional $30 million upon publication of a positive draft EsoGuard Medicare local coverage determination
Series D Preferred Stock convertible into common stock subject to stockholder approval at an upcoming special meeting
New senior secured note with three-year maturity yielded an additional $15 million of gross proceeds
Proceeds used to redeem and retire all previously outstanding convertible securities, eliminating a significant legacy capital structure overhang
Transactions yielded approximately $7.7 million in net cash proceeds, materially strengthening the Company's balance

PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities

Wed, 04 Feb 2026 08:01:00 -0500

Series D Preferred Stock offering yielded $30 million of gross proceeds and includes warrants exercisable for up to an additional $30 million upon publication of a positive draft EsoGuard Medicare local coverage determination
Series D Preferred Stock convertible into common stock subject to stockholder approval at an upcoming special meeting
New senior secured note with three-year maturity yielded an additional $15 million of gross proceeds
Proceeds used to redeem and retire all previously outstanding convertible securities, eliminating a significant legacy capital structure overhang
Transactions yielded approximately $7.7 million in net cash proceeds, materially strengthening the Company's balance

PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities

Wed, 04 Feb 2026 08:01:00 -0500

Series D Preferred Stock offering yielded $30 million of gross proceeds and includes warrants exercisable for up to an additional $30 million upon publication of a positive draft EsoGuard Medicare local coverage determination
Series D Preferred Stock convertible into common stock subject to stockholder approval at an upcoming special meeting
New senior secured note with three-year maturity yielded an additional $15 million of gross proceeds
Proceeds used to redeem and retire all previously outstanding convertible securities, eliminating a significant legacy capital structure overhang
Transactions yielded approximately $7.7 million in net cash proceeds, materially strengthening the Company's balance

PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities

Wed, 04 Feb 2026 08:01:00 -0500

Series D Preferred Stock offering yielded $30 million of gross proceeds and includes warrants exercisable for up to an additional $30 million upon publication of a positive draft EsoGuard Medicare local coverage determination
Series D Preferred Stock convertible into common stock subject to stockholder approval at an upcoming special meeting
New senior secured note with three-year maturity yielded an additional $15 million of gross proceeds
Proceeds used to redeem and retire all previously outstanding convertible securities, eliminating a significant legacy capital structure overhang
Transactions yielded approximately $7.7 million in net cash proceeds, materially strengthening the Company's balance

PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities

Wed, 04 Feb 2026 08:01:00 -0500

Series D Preferred Stock offering yielded $30 million of gross proceeds and includes warrants exercisable for up to an additional $30 million upon publication of a positive draft EsoGuard Medicare local coverage determination
Series D Preferred Stock convertible into common stock subject to stockholder approval at an upcoming special meeting
New senior secured note with three-year maturity yielded an additional $15 million of gross proceeds
Proceeds used to redeem and retire all previously outstanding convertible securities, eliminating a significant legacy capital structure overhang
Transactions yielded approximately $7.7 million in net cash proceeds, materially strengthening the Company's balance

PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities

Wed, 04 Feb 2026 08:01:00 -0500

Series D Preferred Stock offering yielded $30 million of gross proceeds and includes warrants exercisable for up to an additional $30 million upon publication of a positive draft EsoGuard Medicare local coverage determination
Series D Preferred Stock convertible into common stock subject to stockholder approval at an upcoming special meeting
New senior secured note with three-year maturity yielded an additional $15 million of gross proceeds
Proceeds used to redeem and retire all previously outstanding convertible securities, eliminating a significant legacy capital structure overhang
Transactions yielded approximately $7.7 million in net cash proceeds, materially strengthening the Company's balance

Form 8-K PAVmed Inc. For: Jan 21

Fri, 23 Jan 2026 16:31:00 -0500
si-local-file:///var/storage/secattach/20260123/25887606.html

Form 8-K PAVmed Inc. For: Jan 21

Fri, 23 Jan 2026 16:31:00 -0500
si-local-file:///var/storage/secattach/20260123/25887606.html

Lucid Diagnostics receives VA contract for esophageal cancer test

Wed, 21 Jan 2026 08:01:16 -0500

Lucid Diagnostics Inc. (NASDAQ: LUCD) announced it received a contract from the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test. The contract expands access to esophageal precancer testing across the VA healthcare system, which serves more than nine million enrolled veterans annually.

The contract operates under the VA Federal Supply Schedule and includes pre-negotiated pricing for EsoGuard that matches the established Medicare payment rate set by the Centers for Medicare & Medicaid Services. This arrangement allows VA hospitals and healthcare facilities nationwide to access EsoGuard through a single, national VA procurement framework.

"We are proud to partner with the

Lucid Diagnostics receives VA contract for esophageal cancer test

Wed, 21 Jan 2026 08:01:16 -0500

Lucid Diagnostics Inc. (NASDAQ: LUCD) announced it received a contract from the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test. The contract expands access to esophageal precancer testing across the VA healthcare system, which serves more than nine million enrolled veterans annually.

The contract operates under the VA Federal Supply Schedule and includes pre-negotiated pricing for EsoGuard that matches the established Medicare payment rate set by the Centers for Medicare & Medicaid Services. This arrangement allows VA hospitals and healthcare facilities nationwide to access EsoGuard through a single, national VA procurement framework.

"We are proud to partner with the

Lucid Diagnostics receives VA contract for esophageal cancer test

Wed, 21 Jan 2026 08:01:16 -0500

Lucid Diagnostics Inc. (NASDAQ: LUCD) announced it received a contract from the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test. The contract expands access to esophageal precancer testing across the VA healthcare system, which serves more than nine million enrolled veterans annually.

The contract operates under the VA Federal Supply Schedule and includes pre-negotiated pricing for EsoGuard that matches the established Medicare payment rate set by the Centers for Medicare & Medicaid Services. This arrangement allows VA hospitals and healthcare facilities nationwide to access EsoGuard through a single, national VA procurement framework.

"We are proud to partner with the

Lucid Diagnostics receives VA contract for esophageal cancer test

Wed, 21 Jan 2026 08:01:16 -0500

Lucid Diagnostics Inc. (NASDAQ: LUCD) announced it received a contract from the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test. The contract expands access to esophageal precancer testing across the VA healthcare system, which serves more than nine million enrolled veterans annually.

The contract operates under the VA Federal Supply Schedule and includes pre-negotiated pricing for EsoGuard that matches the established Medicare payment rate set by the Centers for Medicare & Medicaid Services. This arrangement allows VA hospitals and healthcare facilities nationwide to access EsoGuard through a single, national VA procurement framework.

"We are proud to partner with the

Lucid Diagnostics receives VA contract for esophageal cancer test

Wed, 21 Jan 2026 08:01:16 -0500

Lucid Diagnostics Inc. (NASDAQ: LUCD) announced it received a contract from the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test. The contract expands access to esophageal precancer testing across the VA healthcare system, which serves more than nine million enrolled veterans annually.

The contract operates under the VA Federal Supply Schedule and includes pre-negotiated pricing for EsoGuard that matches the established Medicare payment rate set by the Centers for Medicare & Medicaid Services. This arrangement allows VA hospitals and healthcare facilities nationwide to access EsoGuard through a single, national VA procurement framework.

"We are proud to partner with the